Study of HB2198 for lupus with moderate to severe symptoms
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have moderate or severe lupus symptoms, as determined by your doctor.
- You need to have had at least one standard lupus treatment that didn't work or caused side effects.
- Your blood tests must show certain antibodies (like ANA) and meet minimum blood cell counts.
- If you have lupus nephritis (kidney involvement), you need a recent kidney biopsy showing active disease.
- You must not have had certain lupus medications (like rituximab) in the last 6 months.
- You cannot be pregnant or breastfeeding and must use birth control if you can become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CRC01, made from your own cells, for people with severe lupus that hasn't improved with standard medications. The goal is to see if it can safely control the disease and reduce symptoms.
This study tests a new drug called HSK39297 combined with standard treatments (steroids and mycophenolate mofetil) for people with active lupus nephritis. It aims to see if the combination is safe and effective in reducing kidney inflammation.
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
This trial tests a new medicine called SHR-2173 for people with active lupus nephritis, a kidney inflammation caused by lupus. The goal is to see if it is safe and effective.
This trial tests a new treatment called ACE1831 for people with moderate to severe lupus that has not improved with standard treatments like steroids or other medications. The goal is to see if it can help control lupus activity.
This trial tests an experimental drug called CLN-978, given as a shot under the skin, that targets a protein on certain immune cells (B cells) to try to calm overactive immune activity in lupus. The goal is to see if it can reduce lupus symptoms for people whose disease has not been controlled by other treatments.
Hear when a new Systemic Lupus Erthematosus (SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.